Vol.

No.

June 23, 2023Jun 23, 2023

DOWNLOAD THE PDF

Jonathan Licht describes University of Florida’s seven-year leap to NCI designation

Cover Story

Conversation with The Cancer Letter

Jonathan Licht describes University of Florida’s seven-year leap to NCI designation

By Paul Goldberg

The University of Florida Health Cancer Center has received NCI Cancer Center designation.

Clinical

In the era of immunotherapy and targeted therapies, ODAC focuses on dose optimization in children

By Jacquelyn Cobb

Free Obituary

Wake Forest’s pioneering radiation oncologist William Blackstock dies at 60

By Ruben A. Mesa and Jenny Kim

Clinical Trials & Tribulations

We need better communication to enable patients to thrive in cancer survivorship

By Lauren Ghazal and Fumiko L. Chino

BSA approves five new, 25 reissue concepts

By Alexandria Carolan

Free In the Archives

Milestones magazine: Documenting NCI CCR research since 2017

Editorial

The Cancer Letter receives 7 journalism, design awards

By Katie Goldberg

In Brief

WVU Cancer Institute receives $50M in state funds to pursue to NCI designation

MD Anderson, Ochsner Health partner to create a fully integrated cancer program in Louisiana

Sunil J. Advani named co-leader of the Cancer Biology and Signaling Program at UCSD Moores

Melody K. Schiaffino named inaugural associate director for equity, diversity, and inclusion at UCSD Moores

UH Cancer Center’s Scott Okamotor receives first Prevention Science Award in Hawai‘i

ASCO Conquer Cancer awards more than $11M to support cancer research

Clinical Roundup

Next-gen Cologuard test demonstrates 94% sensitivity & 91% specificity for CRC

Lancet paper: Treatment with fruquintinib prolongs survival in mCRC

Stanford study: AI outperforms standard of care in prostate cancer identification

Tumor mutation associated with drug-resistant HCC, UT Southwestern study finds

Drugs & Targets

FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer

FDA establishes pilot program to reduce risks associated with cancer biomarker laboratory developed tests

Flatiron partners with Leeds Teaching Hospitals NHS Trust

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Jonathan Licht describes University of Florida’s seven-year leap to NCI designation

In the era of immunotherapy and targeted therapies, ODAC focuses on dose optimization in children

Wake Forest’s pioneering radiation oncologist William Blackstock dies at 60

We need better communication to enable patients to thrive in cancer survivorship

BSA approves five new, 25 reissue concepts

Milestones magazine: Documenting NCI CCR research since 2017

The Cancer Letter receives 7 journalism, design awards

In Brief

WVU Cancer Institute receives $50M in state funds to pursue to NCI designation

MD Anderson, Ochsner Health partner to create a fully integrated cancer program in Louisiana

Sunil J. Advani named co-leader of the Cancer Biology and Signaling Program at UCSD Moores

Melody K. Schiaffino named inaugural associate director for equity, diversity, and inclusion at UCSD Moores

UH Cancer Center’s Scott Okamotor receives first Prevention Science Award in Hawai‘i

ASCO Conquer Cancer awards more than $11M to support cancer research

Clinical Roundup

Next-gen Cologuard test demonstrates 94% sensitivity & 91% specificity for CRC

Lancet paper: Treatment with fruquintinib prolongs survival in mCRC

Stanford study: AI outperforms standard of care in prostate cancer identification

Tumor mutation associated with drug-resistant HCC, UT Southwestern study finds

Drugs & Targets

FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer

FDA establishes pilot program to reduce risks associated with cancer biomarker laboratory developed tests

Flatiron partners with Leeds Teaching Hospitals NHS Trust

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login